VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

S c r o l l

Products

.01

TOTUM-63

Prediabetes, risk condition for Type 2 Diabetes
> Clinical Phase II positive
> Clinical Phase II/III pending

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia, risk factor for cardiovascular diseases
> Clinical Phase II initiated

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis, risk condition for NASH
> Clinical Phase II pending

Learn more

.04

TOTUM-854

Elevated blood pressure, a risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

11.01.2021

J.P. Morgan Healthcare Conference / H.C. Wainwright BioConnect Conference

En savoir plus
02.12.2020

French Healthcare Days Mexico

En savoir plus
18.11.2020

Journées Aliments & Santé

En savoir plus
12.11.2020

Wainwright 6th Annual Israel Conference

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Follow us!

See more